New cutting edge technology can be used to grade cancer tumours, eradicating human subjectivity and ensuring patients get the right treatment.
A new imaging technology to grade tumour biopsies has been developed by a team of scientists led by the Department of Physics and the Department of Surgery and Cancer at Imperial College London.
Publishing their results today in the journal Convergent Science Physical Oncology, they describe how their new method promises to significantly reduce the subjectivity and variability in grading the severity of cancers.
[Digistain] is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis.Professor Chris Phillips
Nearly all cancers are still diagnosed by doctors taking a sample of the tumour, a so-called biopsy, then slicing it thinly and staining it with two vegetable dyes used for more than 100 years. They look at this ‘H+E stained’ sample under a microscope and then judge the severity of the disease by eye alone.
Life-changing treatment decisions have to be based on this ‘grading’ process, yet it is well known that different practitioners given the same slice will only agree on its grade about 70% of the time, resulting in an overtreatment problem.
The team’s new ‘Digistain’ technology addresses this problem by using invisible mid-infrared light to photograph the tissue slices in a way that maps out the chemical changes that signal the onset of cancer. In particular, they measure the ‘nuclear-to-cytoplasmic-ratio’ (NCR): a recognized biological marker for a wide range of cancers.
Lead author Professor Chris Phillips, from the Department of Physics at Imperial, said: “Our machine gives a quantitative ‘Digistain index’ (DI) score, corresponding to the NCR, and this study shows that it is an extremely reliable indicator of the degree of progression of the disease. Because it is based on a physical measurement, rather than a human judgement, it promises to remove the element of chance in cancer diagnosis. “
In the experiment reported today, the team carried out a double-blind clinical pilot trial using two adjacent slices taken from 75 breast cancer biopsies. The first slice was graded by clinicians as usual, using the standard H+E protocol. It was also used to identify the so-called ‘region of interest’ (RoI), i.e. the part of the slice containing the tumour.
The team then used the Digistain imager to get a DI value averaged over the corresponding RoI on the other, unstained slice, and ran a statistical analysis on the results.
Professor Phillips said: “Even with this modest number of samples, the correlation we saw between the DI score and the H+E grade would only happen by chance 1 time in 1400 trials. The strength of this correlation makes us extremely optimistic that Digistain will be able to eliminate subjectivity and variability in biopsy grading.”
Proving its worth
The NCR factor that Digistain measures is known to be common to a wide range of cancers, as it occurs when the reproductive cell cycle gets disrupted in the tumour and cell nuclei get distorted with rogue DNA. It is likely that in the long run, Digistain could help with the diagnosis of all different types of cancer.
At a practical level, the researchers say that the Digistain imaging technology can easily and cheaply be incorporated into existing hospital labs, and be used by their staff. Professor Philips added: “It’s easy to prove its worth by checking it with the thousands of existing biopsy specimens that are already held in hospital archives. Together these facts will smooth the path into the clinic, and it could be saving lives in only a couple of years.”
The Latest on: Cancer diagnosis
via Google News
The Latest on: Cancer diagnosis
Olympic medalist Kikkan Randall announces cancer diagnosis
on July 11, 2018 at 12:49 pm
ANCHORAGE, Alaska -- Olympic gold medalist Kikkan Randall announced Wednesday that she's been diagnosed with early-stage breast cancer. The 35-year-old cross-country skier known for pink highlighted h... […]
Curtis Swanson, CEO at ClearCyte, on Handling a Cancer Diagnosis
on July 11, 2018 at 12:45 pm
This post was contributed by a community member. A cancer diagnosis is never easy to absorb, and unfortunately, many people will have to deal with one at some point in their lives. In 2016, there was ... […]
Alaskan skier Kikkan Randall reveals breast cancer diagnosis
on July 11, 2018 at 12:11 pm
Alaskan skier and Olympic gold medalist Kikkan Randall has cancer, she said in an announcement on Instagram Wednesday morning. “The color pink has taken on a new chapter in my life,” Randall said in h... […]
Olympic Gold Medalist Skier Kikkan Randall Diagnosed With Breast Cancer
on July 11, 2018 at 11:00 am
Olympic gold medalist Kikkan Randall has been diagnosed with breast cancer, Randall announced on social media. Randall, 35, took to Twitter to reveal her diagnosis. "The color pink has taken on a new ... […]
Olympic gold medalist Kikkan Randall diagnosed with breast cancer
on July 11, 2018 at 9:42 am
Olympic gold medalist Kikkan Randall said on social media Wednesday she’s recently been diagnosed with breast cancer. Randall, along with U.S. teammate Jessie Diggins, made history in Pyeongchang by b... […]
ACA credited with earlier diagnosis of gynecologic cancers in young women
on July 11, 2018 at 9:26 am
That's the conclusion of a new study by researchers at Johns Hopkins Medicine, who looked at nationwide trends in gynecologic cancer diagnosis in a large population of women before and after the ACA's ... […]
Kikkan Randall diagnosed with breast cancer, prognosis good
on July 11, 2018 at 9:08 am
Kikkan Randall, who helped the U.S. to its first Olympic cross-country skiing title in PyeongChang, was recently diagnosed with breast cancer. “The color pink has taken on a new chapter in my life as ... […]
Newly Diagnosed Metastatic Renal Cell Carcinoma
on July 11, 2018 at 8:30 am
The busy oncologist treating a patient with metastatic disease now has a plethora of choices for both newly diagnosed and relapsed kidney cancer. In this OncLive ® Peer Exchange ®, my colleagues and I ... […]
Young siblings diagnosed with same brain cancer within weeks of each other
on July 11, 2018 at 6:55 am
Doctors in California are trying to solve a family's stunning medical mystery. Two young siblings, four and six years old, were diagnosed with the same kind of brain tumor within two weeks of each oth... […]
via Bing News